<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04469699</url>
  </required_header>
  <id_info>
    <org_study_id>UKM12_0017</org_study_id>
    <secondary_id>2015-002727-25</secondary_id>
    <nct_id>NCT04469699</nct_id>
  </id_info>
  <brief_title>Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma</brief_title>
  <acronym>NOA11</acronym>
  <official_title>Controlled Clinical Trial to Evaluate the Safety and Efficacy of Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Krebshilfe e.V., Bonn (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>photonamic GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>LifePhotonic GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this multicenter, randomized, non-blinded trial the efficacy and safety of stereotactical
      photodynamic therapy with 5-aminolevulinic acid will be investigated in 106 patients with
      recurrent glioblastoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>through study completion (at least 1.5 years and a maximum of 5 years) or until progression or death</time_frame>
    <description>Progression free survival (PFS) measured as time from the day of randomization until diagnosis of progressive disease as determined by MRI according to RANO criteria (Response Assessment in Neuro-Oncology Criteria) or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-month PFS rate</measure>
    <time_frame>for each patient up to 6 months after randomization or until progression has occurred</time_frame>
    <description>Progression free survival (PFS) measured as time from the day of randomization until diagnosis of progressive disease as determined by MRI according to RANO criteria or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>through study completion (at least 1.5 years and a maximum of 5 years) or until death</time_frame>
    <description>Overall survival (OS) measured as time from the day of randomization until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free time</measure>
    <time_frame>through study completion (at least 1.5 years and a maximum of 5 years) or until progression</time_frame>
    <description>Progression free time as time from the day of randomization until progressive disease (death is regarded as censored)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-month OS rate</measure>
    <time_frame>for each patient up to 12 months after randomization or until death</time_frame>
    <description>Overall survival (OS) measured as time from the day of randomization until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute changes from baseline in contrast medium volume uptake from the MRI performed 48 hours after randomization on, and during any MRI performed thereafter to monitor for disease progression</measure>
    <time_frame>Baseline, 26 - 48 hours after stereotactic procedure, 1 month after randomization and then every 2 months, 1.5 years after randomization or at disease progression, and then every 3 months until end of entire study (up to 5 years) or progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>48h response rate on MRI (Complete Remission, Partial Remission, Stable Disease) after treatment with iPDT (interstitial photodynamic therapy)</measure>
    <time_frame>26 - 48 hours after stereotactic procedure in patients treated with interstitial photodynamic therapy (iPDT)</time_frame>
    <description>Response is assessed according to the RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>If a PET (positron emission tomography) was performed less than 2 weeks apart from an MRI: Consistency of both procedures with regard to the region of interest (ROI)</measure>
    <time_frame>Baseline, 26 - 48 hours after stereotactic procedure, 1 month after randomization and then every 2 months, 1.5 years after randomization or at disease progression and then every 3 months until end of entire study (up to 5 years) or progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in KPS (Karnofsky Performance Score)</measure>
    <time_frame>Baseline, 26 -48 hours after stereotactic procedure, upon discharge or 7 days after stereotactic procedure, 1 month after randomization and then every 2 months until 1.5 years after randomization or disease progression</time_frame>
    <description>Minimum value: 0, maximum value: 100. A higher value means a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NIHSS (National Institutes of Health Stroke Scale)</measure>
    <time_frame>Baseline, 26 -48 hours after stereotactic procedure, upon discharge or 7 days after stereotactic procedure, 1 month after randomization and then every 2 months until 1.5 years after randomization or disease progression</time_frame>
    <description>Minimum value: 0, maximum value: 42. A higher value means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MMSE (Mini-Mental State Examination)</measure>
    <time_frame>Baseline, 26 -48 hours after stereotactic procedure, upon discharge or 7 days after stereotactic procedure, 1 month after randomization and then every 2 months until 1.5 years after randomization or disease progression</time_frame>
    <description>Minimum value: 0, maximum value: 30. A higher value means a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain edema as assessed by MRI within 26 to 48 h after stereotactic surgery</measure>
    <time_frame>26 to 48 hours after stereotactic intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>over the entire study period of each patient (at least 1.5 years and a maximum of 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire) score during study participation</measure>
    <time_frame>Baseline, at discharge or 7 days after intervention, 1 month after randomization and then every 2 months, 1.5 years after randomization or at disease progression and then every 3 months until end of entire study (up to 5 years) or progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the EORTC QLQ-BN20 module (European Organisation for Research and Treatment of Cancer Quality of Life Brain Cancer Module) score during study participation</measure>
    <time_frame>Baseline, at discharge or 7 days after intervention, 1 month after randomization and then every 2 months, 1.5 years after randomization or at disease progression and then every 3 months until end of entire study (up to 5 years) or progression</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Glioblastoma Multiforme, Adult</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic biopsy followed by stereotactical photodynamic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stereotactic biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stereotactic biopsy followed by stereotactical photodynamic therapy with 5-aminolevulinic acid</intervention_name>
    <description>5-ALA HCl orally (20 mg/kg bw) 3,5-4,5 hours prior to induction of anaesthesia for stereotactic biopsy followed by stereotactical photodynamic therapy. All patients will receive further treatment of recurrent glioblastoma at the investigator´s discretion (best possible care).</description>
    <arm_group_label>Treatment arm</arm_group_label>
    <other_name>Gliolan, 5-aminolevulinic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stereotactic biopsy</intervention_name>
    <description>Stereotactic biopsy. All patients will receive further treatment of recurrent glioblastoma at the investigator´s discretion (best possible care).</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent

          2. Age 18 - 75 years

          3. Karnofsky Performance Score (KPS) of ≥60 %

          4. Radiologically suspected diagnosis (according to RANO criteria) of the first
             recurrence of a glioblastoma located in the cerebral hemisphere including insular and
             diencephalon. Tumors in the brain stem are excluded. First MRI with signs of first
             recurrence (radiologic RANO criteria for disease progression) within 8 weeks prior to
             Informed Consent. Not necessarily identical to primary tumor location

          5. Single or single progressive contrast-enhancing lesion on MRI, largest diameter not
             more than 2.5 cm

          6. For female and male patients of reproductive potential: Willingness to apply highly
             effective contraception (Pearl index &lt;1) during the entire study

        Exclusion Criteria:

          1. Multifocal disease &gt; 2 locations

          2. Patients with significant non-enhancing tumor portions

          3. Previous treatment of recurrence

          4. Other malignant disease except basalioma

          5. Hypersensitivity against porphyrins or Gliolan® or Fluorethylenpropylen (FEP )

          6. Porphyria

          7. HIV infection, active Hepatitis B or C infection

          8. Bone marrow reserve:

               -  white blood cell (WBC) count &lt;2000/μl,

               -  platelets &lt;100000/μl,

          9. Liver function:

               -  total bilirubin &gt; 1.5 times above upper limit of normal range (ULN)

               -  alanine transaminase (ALT) and aspartate transaminase (AST) &gt; 3 times ULN

         10. Renal function:

             - creatinine &gt; 1.5 times ULN

         11. Blood clotting:

             - Quick/INR or PTT out of acceptable limits

         12. Conditions precluding MRI (e.g. pacemaker)

         13. Past medical history of diseases with poor prognosis, e.g. severe coronary heart
             disease, heart failure (NYHA III/IV), severe poorly controlled diabetes, immune
             deficiency, residual deficits after stroke, severe mental retardation or other serious
             concomitant systemic disorders incompatible with the study (at the discretion of the
             investigator)

         14. Any active infection (at the discretion of the investigator)

         15. Any psychological, cognitive, familial, sociological or geographical condition that,
             in the investigator's opinion, compromises the patient's ability to understand the
             patient information, to give informed consent or to comply with the trial protocol

         16. Previous antiangiogenic treatment

         17. Participation in another interventional clinical trial during this trial or within 4
             weeks before entry into this trial.

         18. Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Stummer, Univ.-Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Muenster, Klinik und Poliklinik für Neurochirurgie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juliane Schroeteler, Dr. med.</last_name>
    <phone>+491733802878</phone>
    <email>juliane.schroeteler@ukmuenster.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medizinische Fakultät Carl Gustav Carus, Klinik und Poliklinik für Neurochirurgie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Klinik für Neurochirurgie, Abteilung Funktionelle NC &amp; Stereotaxie</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik für Neurochirurgie und Wirbelsäulenchirurgie</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU München, Campus Großhadern, Neurochirurgische Klinik und Poliklinik</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Klinik und Poliklinik für Neurochirurgie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>July 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

